Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
Markets in Asia fell on Wednesday morning after U.S. Federal Reserve Chairman Jerome Powell tempered expectations for a potential interest rate cut.Asia Marketsread more
In a text message, Grisham confirmed to CNBC that she will still be working for the first lady even as she takes on her new roles.Politicsread more
Acting Customs and Border Protection Commissioner John Sanders is resigning amid the furor over the Trump administration's treatment of migrant children.Politicsread more
NBC is taking the office back from Netflix as it seeks to bolster its own streaming service launching in 2020.Technologyread more
Wayfair employees plan to walk out tomorrow, after no action was taken in response to their opposition to the company supplying border detention camps with beds for children.Retailread more
Micron beat analyst estimates on earnings and revenue for its fiscal third quarter of 2019.Technologyread more
Omarosa Manigault Newman, who had been a senior advisor to President Donald Trump before her firing, was sued for allegedly failing to file required financial disclosures.Politicsread more
The Food and Drug Administration is discouraging people from being infused with young blood, a procedure that's becoming increasingly common but hasn't been proven to have medical benefits.
The procedure works like it sounds. People are infused with blood plasma donated from young people. Some clinics claim the procedure works like a fountain of youth to reverse aging and memory loss or even treat diseases like dementia, Parkinson's disease, multiple sclerosis, Alzheimer's, heart disease or post-traumatic stress disorder.
Companies typically charge thousands of dollars for the treatments. That concerns the FDA, which says these infusions are "unproven and not guided by evidence from adequate and well-controlled trials."
"Simply infusing plasma is not a benign intervention and should not be used in such cavalier fashion," FDA Commissioner Scott Gottlieb told CNBC in a phone interview Tuesday.
New treatments must undergo numerous studies to demonstrate whether they're safe and effective. The FDA reviews and scrutinizes the data before determining whether treatments can enter the market.
Young blood infusions have not gone through this testing. The FDA does not recognize plasma to treat aging, memory loss or other diseases. Therefore, consumers should not assume them to be safe or effective, Gottlieb said.
"We have a lot of public health concerns. This is not an appropriate use of plasma," he said.
In addition to there being "no compelling clinical evidence on its efficacy," the FDA says there's no information on the appropriate dosing. The agency is concerned with how much young plasma these clinics are pumping into patients. Large volumes of plasma can be associated with "significant risks," including infections, allergies and respiratory and cardiovascular reactions, Gottlieb said.
The agency may pursue enforcement actions against companies offering these infusions, a process that can take months. It's starting with a warning to consumers because the agency's has immediate concerns, Gottlieb said.